Group 1 - The core point of the article is that Hefei Lifan Pharmaceutical has received approval for the production of Danpi Phenol, which enhances its raw material supply capacity and competitiveness in the market [1] - The new production process for Danpi Phenol is environmentally friendly and cost-effective, allowing for capacity expansion while meeting market demand [1] - The approval of Danpi Phenol is part of a series of product approvals this year, including the approval for the raw material of Docusate Sodium, which further enriches the company's product pipeline [1] Group 2 - The company has also received a clinical trial approval for Beipiduo Acid Tablets, marking a significant step in the development of lipid-lowering drugs and establishing a foundation for expansion in the cardiovascular treatment market [2] - Beipiduo Acid Tablets were originally approved in the U.S. in 2020, and Lifan Pharmaceutical is the third company in China to receive clinical approval, providing it with a first-mover advantage in this field [2] - The biopharmaceutical industry is projected to grow significantly, with the market size expected to reach 2.24 trillion yuan by 2025, indicating a competitive landscape where companies with core technologies and innovation capabilities are likely to succeed [2]

立方制药（003020）公告，公司收到国家药品监督管理局下发的贝派度酸片《药物临床试验批准通知 书》。贝派度酸片是一种三磷酸腺苷-柠檬酸裂解酶抑制剂，通过抑制肝脏中胆固醇的合成来降低LDL- C。该产品原研药于2020年在美国获批上市，尚未在国内上市。本次注册申请分类为化学药品3类。国 家药品监督管理局药品审评中心数据显示，公司为国内第3家获批临床企业。贝派度酸片药品临床试验 申请获得批准，对公司短期业绩不会产生重大影响。 ...